Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Licenses Mammalian RNAi Patent Application from Stanford

Premium

Alnylam said this week that it has co-exclusively licensed from Stanford University the therapeutic rights to a patent application covering RNAi-mediated inhibition of gene expression in mammals, as well as related technology.

The patent application (numbered 20030153519 and filed on July 19, 2002) specifically claims the delivery of an “RNAi agent” — including interfering ribonucleic acid, such as an siRNA or shRNA, or a transcription template thereof, such as a DNA encoding an shRNA — to a non-embryonic mammal “via a hydrodynamic administration protocol.” Also covered under the application are “RNAi agent pharmaceutical preparations for use in subject methods.”

Specific terms of the arrangement were not disclosed.

The deal with Stanford comes less than two months after Alnylam signed separate deals to license patent applications from Cancer Research Technology and MIT related to inhibiting gene expression with dsRNA and drug delivery techniques for nucleic acid compounds, respectively.

Alnylam has been pushing since its inception to establish a firm IP foundation, acquiring German peer Ribopharma in July partly for its patent estate.

 

The Scan

Vaccine Update Recommended

A US Food and Drug Administration panel recommends booster vaccines be updated to target Omicron, CNBC reports.

US to Make More Vaccines for Monkeypox Available

The US is to make nearly 300,000 vaccine doses available in the coming weeks to stem the spread of human monkeypox virus, according to NPR.

Sentence Appealed

The Associated Press reports that Swedish prosecutors are appealing the sentence given to a surgeon once lauded for transplanting synthetic tracheas but then convicted of causing bodily harm.

Genome Biology Papers on COVID-19 Effector Genes, Virtual ChIP-seq, scDART

In Genome Biology this week: proposed COVID-19 effector genes, method to predict transcription factor binding patterns, and more.